Alan C. Cheng
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Protein Structure and Dynamics, Monoclonal and Polyclonal Antibodies Research, Machine Learning in Materials Science, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → Structure-based maximal affinity model predicts small-molecule druggability(2007)687 cited
- → AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies(2018)409 cited
- → Improvement in ADMET Prediction with Multitask Deep Featurization(2020)192 cited
- → Recognition of Nucleic Acid Bases and Base-pairs by Hydrogen Bonding to Amino Acid Side-chains(2003)142 cited
- → Structure of the Catalytic Domain of Human Polo-like Kinase 1,(2007)123 cited
- → Structure guided design of a series of sphingosine kinase (SphK) inhibitors(2013)98 cited
- → Deep Learning Approaches in Predicting ADMET Properties